By Fineline Cube 
C‑MER Eye Care Medical Group Limited (HKG: 3309) on 26 August, 2025 disclosed plans to acquire a 58 % stake in Hong Kong Endoscopic Diagnosis and Therapy Centre Limited (trading as Hong Kong Endoscopy Centre), the operation’s major shareholder being set to become a full‑time subsidiary of C‑MER Medical. The deal is expected to close in or around October 2025.
Deal Highlights
| Item | Detail |
|---|---|
| Acquisition Target | Hong Kong Endoscopic Diagnosis and Therapy Centre Limited |
| Stake Acquired | 58 % of issued share capital |
| Transaction Value | Not disclosed |
| Closing Date | ~October 2025 |
| Post‑Deal Structure | Hong Kong Endoscopy Centre becomes a C‑MER subsidiary |
About Hong Kong Endoscopy Centre
- Founded: 2016
- Location: Grand Plaza, Mongkok, Hong Kong
- Facilities: Three endoscopy suites
- Core Services: Gastroscopy, colonoscopy, cystoscopy
Strategic Rationale
- Geographic Expansion: Strengthens C‑MER’s footprint in Hong Kong’s diagnostic and therapeutic market.
- Service Synergy: Combines C‑MER’s ophthalmic expertise with Hong Kong Endoscopy’s established endoscopic capabilities, opening avenues for cross‑specialty referrals.
- Growth Trajectory: Adds a proven, high‑volume provider to C‑MER’s portfolio, supporting its broader Asian expansion strategy.
Market Impact
Analysts note that the acquisition positions C‑MER as a more diversified healthcare player, potentially attracting new investors and enhancing its valuation. The transaction also reflects a broader trend of consolidation in Hong Kong’s specialty medical services sector.-Fineline Info & Tech